MindMed Archives

Psychedelics News

MindMed

Industry

3 May 2023

MindMed Drama: Freemans Attempt Board of Directors Takeover

The drama continues at MindMed. The (former?) fan-favorite has had a rough run, facing an industry-wide drop in share price while dealing with a string of scenarios that have (rightly...

By Jason Najum

Science

26 Apr 2023

What is LSD? A Look at LSD Clinical Trials

To celebrate Bicycle Day, Microdose is devoting the month of April to an exploration of LSD. To help answer the question of what is LSD? we’re taking a closer look...

By Microdose

Industry

18 Apr 2023

LSD Decreased Depression Symptoms by 50% in New MindMed Study

On April 14th, psychedelic medicine company MindMed (Nasdaq: MNMD, NEO: MMED) released preliminary data from a Phase 2 clinical trial, which attempted to treat Major Depressive Disorder (MDD) with LSD-assisted...

By James Hallifax

Industry

14 Apr 2023

MindMed Announces Positive Data from Phase 2 LSD Trial for Depression

One of MindMed’s most valuable assets is its deal with the University Hospital Basel and its research team led by Dr....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

11 Jan 2023

Key Takeaways from MindMed’s 2023 Corporate Update

On January 9th, psychedelic medicine company MindMed (Nasdaq: MNMD, NEO:MMED) released its 2023 corporate update....

By James Hallifax

Industry

4 Jan 2023

Top 3 Psychedelic Storylines to Watch in 2023

2022 was a milestone year for the psychedelic industry, and 2023 is shaping up to be an even more paradigm-shifting....

By James Hallifax

Industry

30 Dec 2022

2022 End-of-Year Review: MindMed

Continuing our series of 2022 end-of-year reviews, we take a look at MindMed’s last 12 months....

By Jason Najum

Industry

20 Dec 2022

Top 5 Psychedelic Milestones of 2022

2022 was a big year for psychedelic medicine industry, we take a look at the top 5 psychedelic milestones for 2022...

By James Hallifax

Industry, Science

30 Nov 2022

New MindMed Study Shortens Trip with “LSD-Neutralizer”

MindMed collaborators published a paper showing that the administration of ketanserin, effectively ends LSD’s psychedelic experience within 2....

By James Hallifax

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result